Efficacy of Low Dose Sofosbuvir and Daclatasvir in Treatment of Chronic Hepatitis C in End Stage Renal Disease
Ahmar Ijaz, Mateen Akram, Shahid Anwar, Azhar Ali Khan, Qazi Saboor, Ibad-ur-Rehman
140
ABSTRACT
Background: Chronic hepatitis C infection is common in patients with end stage renal
disease. The management of hepatitis C virus infection has been greatly
influenced by the availability of direct acting antivirals.
Aim: To determine the efficacy of low dose Sofosbuvir and Daclatasvir in
treatment of chronic hepatitis C in patients with end stage renal disease.
Study design:
Descriptive case series.
Place and study
duration: The study was conducted in the Department of
Nephrology at Shaikh Zayed Hospital, Lahore from 24th March, 2019 to
23rd September, 2019.
Methodology:
A total of 180 patients were enrolled in the
study. Serum load of HCV was performed by PCR at baseline, and patients were
started on low dose of Sofosbuvir (200mg) and Daclatasvir (60mg), once a day
orally for 12 weeks and treatment efficacy was re-assessed by PCR after 12
weeks.
Results: A total of 180 patients were enrolled in the study. The mean age of the
patients was 40.53±11.210, mean number of dialysis sessions was 13.98±7.96.
There were 59.9% males and 41.1% females. Treatment was efficacious in 91.7% of
the patients. Side effects associated with treatment were fatigue (23.9%),
nausea (12.8%), headache (11.7%) and anemia (5%). No effect was seen of age,
gender, number of dialysis sessions and previous history of treatment on
efficacy of treatment.
Conclusion: Low dose Sofosbuvir and Daclatasvir were effective in the treatment of
hepatitis C infection in patients with end stage renal disease and had a good
safety profile.
Keywords: End Stage Renal Disease, Chronic Hepatitis C, Direct Acting Antiviral
Agent
ABSTRACT
Background: Chronic hepatitis C infection is common in patients with end stage renal
disease. The management of hepatitis C virus infection has been greatly
influenced by the availability of direct acting antivirals.
Aim: To determine the efficacy of low dose Sofosbuvir and Daclatasvir in
treatment of chronic hepatitis C in patients with end stage renal disease.
Study design:
Descriptive case series.
Place and study
duration: The study was conducted in the Department of
Nephrology at Shaikh Zayed Hospital, Lahore from 24th March, 2019 to
23rd September, 2019.
Methodology:
A total of 180 patients were enrolled in the
study. Serum load of HCV was performed by PCR at baseline, and patients were
started on low dose of Sofosbuvir (200mg) and Daclatasvir (60mg), once a day
orally for 12 weeks and treatment efficacy was re-assessed by PCR after 12
weeks.
Results: A total of 180 patients were enrolled in the study. The mean age of the
patients was 40.53±11.210, mean number of dialysis sessions was 13.98±7.96.
There were 59.9% males and 41.1% females. Treatment was efficacious in 91.7% of
the patients. Side effects associated with treatment were fatigue (23.9%),
nausea (12.8%), headache (11.7%) and anemia (5%). No effect was seen of age,
gender, number of dialysis sessions and previous history of treatment on
efficacy of treatment.
Conclusion: Low dose Sofosbuvir and Daclatasvir were effective in the treatment of
hepatitis C infection in patients with end stage renal disease and had a good
safety profile.
Keywords: End Stage Renal Disease, Chronic Hepatitis C, Direct Acting Antiviral
Agent